European Partnership on Rare Diseases (ERDERA) (Phase 2)
This grant funds the next phase of the European Partnership on Rare Diseases, supporting cutting-edge research, data sharing, and clinical innovation to improve rare disease care across Europe.
This grant is no longer accepting proposals
European Commission has archived this opportunity.
Funder: European Commission
Due Dates: September 15, 2026 (Full application, ERDERA Phase 2) | September 14, 2026 (Call-level deadline)
Funding Amounts: ~€91.3M total (2026–2027); single grant; 50% funding rate; max €10M per third party for financial support
Summary: Funds the continuation and expansion of the European Partnership on Rare Diseases, advancing EU leadership in rare disease research, data sharing, and healthcare innovation.
Key Information: Only the existing ERDERA consortium (HORIZON-HLTH-2023-DISEASE-07-01) may apply; new partners may be added.
Description
This funding opportunity supports Phase 2 of the European Partnership on Rare Diseases (ERDERA), a major co-funded initiative under Horizon Europe. The partnership aims to reinforce the EU’s leadership in rare disease research and innovation by strengthening cross-border data access, improving translational research, and fostering equitable access to innovative healthcare for people with rare diseases. The program seeks to align research policies, build integrated data infrastructures, support clinical trial readiness, and promote multi-stakeholder collaboration across Europe and globally.
The partnership will implement a long-term Strategic Research and Innovation Agenda (SRIA), launch joint calls for research, support the development of clinical research networks, and enable capacity building for the rare disease data ecosystem. Activities will include financial support to third parties (notably through joint transnational calls), clinical research infrastructure development, and integration of research across the R&I continuum to maximize impact and reduce redundancies. The action is expected to contribute to EU health strategies, the European Health Data Space, and international initiatives such as the International Rare Disease Research Consortium (IRDiRC).
